635. Efficacy, Pharmacokinetics (PK), and Safety Profile of MEDI3902, an Anti-<i>Pseudomonas aeruginosa</i> Bispecific Human Monoclonal Antibody in Mechanically Ventilated Intensive Care Unit Patients; Results of the Phase 2 EVADE Study Conducted by the Public-Private COMBACTE-MAGNET Consortium in the Innovative Medicines Initiative (IMI) Program
Jean Chastre(Inserm), Hasan S. Jafri(AstraZeneca (Australia)), Filip Dubovsky(University of Maryland, Baltimore), Alexey Ruzin(AstraZeneca (United States)), Miguel Sánchez García(Hospital Clínico San Carlos), Terramika Bellamy(AstraZeneca (United States)), Ricard Ferrer(Universitat Autònoma de Barcelona), İftihar Köksal(Karadeniz Technical University), Charles‐Édouard Luyt(Inserm), Thomas L Holland(Duke University), Alain Lepape(Hospices Civils de Lyon), Pin Ren(AstraZeneca (United States)), Kathryn Shoemaker(AstraZeneca (United States)), Nicolas De Schryver(Clinique Saint Pierre), Susan Colbert(AstraZeneca (United States)), Marc Bourgeois(AZ Sint-Jan), Colin Reisner(Reproductive Medicine Associates of New Jersey), Omar Ali(AstraZeneca (United States)), Antoni Torres(Instituto de Salud Carlos III), Bruno François(Inserm), Galia Rahav(Tel Aviv University), Apostolos Komnos(University Hospital of Larissa), Yu Jiang(AstraZeneca (United States)), Drieke Vandamme(Inserm)
Cited by 16
Related Papers
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
|Clinical Microbiology Reviews|2015|5.1k
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Critical Care Medicine|2017|3.8k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
|Critical Care Medicine|2021|2.8k